GW Pharmaceuticals PLC (GWPH) Given Outperform Rating at Leerink Swann
GW Pharmaceuticals PLC (NASDAQ:GWPH)‘s stock had its “outperform” rating reiterated by equities research analysts at Leerink Swann in a research note issued on Thursday. They currently have a $160.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $162.00. Leerink Swann’s target price would indicate a potential upside of 59.17% from the company’s current price.
Other equities research analysts also recently issued reports about the company. Maxim Group set a $135.00 price target on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Monday. ValuEngine raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Zacks Investment Research downgraded GW Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a research note on Monday, May 15th. BidaskClub raised GW Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, June 21st. Finally, Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the company a “buy” rating in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. GW Pharmaceuticals PLC currently has a consensus rating of “Buy” and an average price target of $147.94.
Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) opened at 100.52 on Thursday. GW Pharmaceuticals PLC has a one year low of $79.62 and a one year high of $137.88. The stock’s market cap is $2.54 billion. The stock’s 50 day moving average price is $105.72 and its 200-day moving average price is $113.95.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.73) by $0.34. GW Pharmaceuticals PLC had a negative return on equity of 27.57% and a negative net margin of 1,384.41%. The firm had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $2.10 million. During the same period last year, the business earned ($0.05) earnings per share. On average, equities analysts predict that GW Pharmaceuticals PLC will post ($5.10) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/08/10/gw-pharmaceuticals-plc-gwph-given-outperform-rating-at-leerink-swann.html.
Hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Arbitrage SA acquired a new stake in GW Pharmaceuticals PLC during the second quarter worth about $163,000. Blair William & Co. IL acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth about $207,000. Nwam LLC acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth about $208,000. Ameriprise Financial Inc. acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth about $230,000. Finally, Quantbot Technologies LP acquired a new stake in GW Pharmaceuticals PLC during the first quarter worth about $231,000. 75.77% of the stock is currently owned by hedge funds and other institutional investors.
GW Pharmaceuticals PLC Company Profile
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.